O-36: Combination Therapy of Traumatic Brain Injury in Rats with a Stem Cell Mobilization by Granulocyte-Colony Stimulating Factor and Human Umbilical Cord Matrix Stem Cell(Wharton Jelly Stem Cell) Intravenous Injection Enhances Functional Recovery


Marzban M *, Bakhtiary M , Mehdizadeh M , Taghi Joghataei M , DehKhoei S , Pirhajati Mahabadi V , Tondar M ,

0

Objective: Arisening clinical studies of treating traumatic brain injury (TBI) and with autologous adult stem cells led us to inquire the stimulus of a combination therapy by intravenous injection of human umbilical cord matrix stem Cell (Wharton jelly stem cell) with bone marrow cell mobilization faradic by granulocytecolony stimulating factor (G-CSF) in rats injured with cortical compact device. Materials and Methods: Adult male Wistar rats (n = 50) were injured with controlled cortical impact device and divided into five groups. The treatment groups (n = 10) were injected with 2 × 106 intravenously human umbilical cord matrix stem cell and were injected with G-CSF subcutaneous and combination therapy group with G-CSF and human umbilical cord matrix stem Cell(Wharton jelly stem cell). Vehicle group (n=10) received phosphate buffered saline (PBS) and only Brdu intraperitoneally. All injections were performed 1 day after injury into the tail veins of rats. All cells label with Brdu before injection into the tail veins of rats. Neurological functional evaluation of animalswas performed before and after injury using Modified Neurological Severity Scores (mNSS). Animals were sacrificed 42 days after TBI and brain sections were stained by Brdu immunohistochemistry. Results: Statistically significant improvement in functional outcome was observed in treatment groups when compared with control (p<0.01). This benefit was visible 7 days after TBI and persisted until 42 days. Modified Neurological Severity Scores (mNSS) showed no significant differences among the HUCMSc (hUCMSC) and G-CSF treated groups at any time point (end of trial). Rats with HUCMSc + G-CSF treatment had a significant improvement on mNSS 5 and 6 week compared to other treatment group (p<0.01). Histological analysis showed in G-CSF+ hUCMSC treated traumatic rats exhibited more significantly increased numbers of Brdu immunoreactive cells in their traumatic core compared with other labeled group. Conclusion: In brief, our data suggest that G-CSF interaction with hUCMSC may be promotes angiogenesis and neurogenesis after TBI that may benefit neurological functional recovery. Nevertheless, other questions, for example the molecular and genetic origin of this neural recovery caused by HUCMSc need more investigations. This therapeutic improvement of combination treatment may beimputed to the increased plasticity. These data propone thatpharmacological therapy may intensify cellular therapy andproduce therapeutic advantage after TBI. More studies, comprising long-term result mensuration are needed. The intendment of the current study makes a great movement toward the expansion of a combined treatment for TBI